Clinical Trials
Peptide clinical trial explorer.
Search public clinical trials by peptide, sponsor, indication, phase, and status. Data sourced from public trial registries.
Last updated
Jul 15, 2026
Source
ClinicalTrials.govVerified
NCT identifiers verified against public registry
Data provider
ClinicalTrials.gov API v2
Educational research platform — not medical or investment advice. Verify all data before decisions.
Phase
Indication
Sponsor
10 of 10 trials
| NCT ID | Title | Phase | Status | Sponsor | Indication | Primary completion |
|---|---|---|---|---|---|---|
| NCT03574597 | SUSTAIN — semaglutide long-term outcomes | Phase 3 | Completed | Novo Nordisk | Type 2 Diabetes | 8/1/2018 |
| NCT03693430 | STEP — semaglutide in obesity | Phase 3 | Completed | Novo Nordisk | Obesity | 3/1/2020 |
| NCT04184622 | SURPASS — tirzepatide in T2D | Phase 3 | Completed | Eli Lilly | Type 2 Diabetes | 2/1/2021 |
| NCT04255433 | SURMOUNT — tirzepatide in obesity | Phase 3 | Completed | Eli Lilly | Obesity | 4/1/2022 |
| NCT05929066 | TRIUMPH — retatrutide obesity program | Phase 3 | Recruiting | Eli Lilly | Obesity | 11/1/2026 |
| NCT05567796 | REDEFINE — CagriSema in obesity | Phase 3 | Active, not recruiting | Novo Nordisk | Obesity | 1/1/2026 |
| NCT06077864 | SYNCHRONIZE-1 — survodutide in obesity | Phase 3 | Recruiting | Zealand Pharma | Obesity | 6/1/2027 |
| NCT05669599 | MariTide obesity Phase 2 | Phase 2 | Active, not recruiting | Amgen | Obesity | 6/1/2026 |
| NCT05203237 | VK2735 obesity Phase 2 | Phase 2 | Active, not recruiting | Viking Therapeutics | Obesity | 12/1/2025 |
| NCT05989711 | IMPACT — pemvidutide in MASH | Phase 2 | Recruiting | Altimmune | MASH | 4/1/2026 |